Integrated Diagnostics Reels In $47 Million To Push Launch Of Lung Cancer Diagnostic
Lung cancer diagnostic company Integrated Diagnostics launched its first product last fall, and now it has plenty of cash to go out and sell it. The firm, which grew out of Seattle’s Institute for Systems Biology and the California Institute of Technology, said Tuesday it has raised $47 million in equity and debt. The cash influx, $30.25 million of which is the company’s Series B equity round, would be a sizable second financing for any biotech. For a diagnostics firm, it’s a windfall.
Help employers find you! Check out all the jobs and post your resume.